Payment overview · 2025
General Payments
$458.81
24 reported records · 7 companies
Healthcare provider profile · identity verified
James Paul Tompkins, MD
Allopathic & Osteopathic Physicians|Family Medicine · BYRDSTOWN, TN · NPI 1508057159
Verified facts
What the public records show
CMS Open Payments records show James Paul Tompkins, MD received $458.81 in general payments during 2025 across 24 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 33.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Rybelsus.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 295 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $153.89 | 33.5% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $103.09 | 22.5% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $99.64 | 21.7% | 6 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.91 | 7.8% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $24.46 | 5.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24.06 | 5.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.76 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $458.81 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $84.60 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.09 | 5 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $69.29 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $69.02 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $61.34 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.75 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.75 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $35.91 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $24.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 133 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 295 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 174 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
133 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
295 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
174 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 933 | 205 |
| Pantoprazole Sodium | Pantoprazole Sodium | 751 | 155 |
| Gabapentin | Gabapentin | 732 | 127 |
| Levothyroxine Sodium | Levothyroxine Sodium | 670 | 142 |
| Amlodipine Besylate | Amlodipine Besylate | 669 | 153 |
| Lisinopril | Lisinopril | 629 | 158 |
| Omeprazole | Omeprazole | 480 | 123 |
| Furosemide | Furosemide | 467 | 119 |
| Losartan Potassium | Losartan Potassium | 436 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 426 | 102 |
| Metoprolol Tartrate | Metoprolol Tartrate | 401 | 98 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 401 | 107 |
| Trazodone Hcl | Trazodone Hcl | 335 | 81 |
| Hydrochlorothiazide | Hydrochlorothiazide | 320 | 81 |
| Metformin Hcl Er | Metformin Hcl | 314 | 79 |
| Mounjaro | Tirzepatide | 295 | 46 |
| Potassium Chloride | Potassium Chloride | 295 | 70 |
| Metoprolol Succinate | Metoprolol Succinate | 281 | 69 |
| Metformin Hcl | Metformin Hcl | 276 | 76 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 276 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 271 | 56 |
| Meloxicam | Meloxicam | 261 | 61 |
| Eliquis | Apixaban | 260 | 53 |
| Carvedilol | Carvedilol | 225 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 72 |
| Famotidine | Famotidine | 212 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 209 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 206 | 47 |
| Doxycycline Hyclate | Doxycycline Hyclate | 203 | 154 |
| Montelukast Sodium | Montelukast Sodium | 198 | 36 |
| Atenolol | Atenolol | 184 | 39 |
| Mirtazapine | Mirtazapine | 182 | 42 |
| Azithromycin | Azithromycin | 175 | 137 |
| Fluticasone Propionate | Fluticasone Propionate | 174 | 58 |
| Ozempic | Semaglutide | 174 | 32 |
| Tramadol Hcl | Tramadol Hcl | 165 | 47 |
| Allopurinol | Allopurinol | 163 | 46 |
| Lorazepam | Lorazepam | 162 | 33 |
| Spironolactone | Spironolactone | 159 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 155 | 37 |
| Buspirone Hcl | Buspirone Hcl | 154 | 27 |
| Simvastatin | Simvastatin | 152 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 151 | 35 |
| Sertraline Hcl | Sertraline Hcl | 146 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 140 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 139 | 36 |
| Pregabalin | Pregabalin | 134 | 23 |
| Jardiance | Empagliflozin | 133 | 27 |
| Clonazepam | Clonazepam | 127 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 37 |
| Glimepiride | Glimepiride | 125 | 31 |
| Alprazolam | Alprazolam | 124 | 19 |
| Cefdinir | Cefdinir | 124 | 107 |
| Celecoxib | Celecoxib | 121 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 120 | 27 |
| Dexamethasone | Dexamethasone | 118 | 102 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 116 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 115 | 27 |
| Clonidine Hcl | Clonidine Hcl | 111 | 31 |
| Ondansetron Odt | Ondansetron | 110 | 51 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 104 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 100 | 25 |
| Quetiapine Fumarate | Quetiapine Fumarate | 100 | 13 |
| Prednisone | Prednisone | 99 | 58 |
| Fluconazole | Fluconazole | 97 | 54 |
| Solifenacin Succinate | Solifenacin Succinate | 94 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 94 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 93 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 93 | 48 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 91 | 65 |
| Xarelto | Rivaroxaban | 83 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 24 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 81 | 15 |
| Benazepril Hcl | Benazepril Hcl | 80 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 79 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 18 |
| Sucralfate | Sucralfate | 73 | 21 |
| Bupropion Xl | Bupropion Hcl | 71 | 14 |
| Nifedipine Er | Nifedipine | 71 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 71 | 11 |
| Synthroid | Levothyroxine Sodium | 69 | 22 |
| Trulicity | Dulaglutide | 66 | 13 |
| Warfarin Sodium | Warfarin Sodium | 66 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 17 |
| Nystatin | Nystatin | 64 | 25 |
| Amitriptyline Hcl | Amitriptyline Hcl | 63 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 63 | 19 |
| Testosterone Cypionate | Testosterone Cypionate | 62 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 61 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 61 | suppressed |
| Baclofen | Baclofen | 60 | 17 |
| Ezetimibe | Ezetimibe | 60 | 14 |
| Levofloxacin | Levofloxacin | 60 | 47 |
| Dicyclomine Hcl | Dicyclomine Hcl | 59 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 17 |
| Promethazine Hcl | Promethazine Hcl | 59 | 15 |
| Amoxicillin | Amoxicillin | 58 | 42 |
| Finasteride | Finasteride | 58 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 57 | 12 |
| Gemfibrozil | Gemfibrozil | 57 | suppressed |
| Diazepam | Diazepam | 56 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 55 | 16 |
| Ibuprofen | Ibuprofen | 55 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 14 |
| Lovastatin | Lovastatin | 54 | 11 |
| Donepezil Hcl | Donepezil Hcl | 53 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 52 | 15 |
| Glipizide | Glipizide | 51 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 51 | 17 |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 46 | suppressed |
| Levetiracetam | Levetiracetam | 46 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 45 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 44 | suppressed |
| Estradiol | Estradiol | 42 | 14 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 42 | 12 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 42 | 12 |
| Primidone | Primidone | 42 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 41 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 33 |
| Enalapril Maleate | Enalapril Maleate | 38 | 11 |
| Januvia | Sitagliptin Phosphate | 37 | suppressed |
| Lamotrigine | Lamotrigine | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 35 | 20 |
| Valacyclovir | Valacyclovir Hcl | 35 | 19 |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Metronidazole | Metronidazole | 34 | 29 |
| Risperidone | Risperidone | 34 | suppressed |
| Bumetanide | Bumetanide | 33 | suppressed |
| Mupirocin | Mupirocin | 33 | 26 |
| Colesevelam Hcl | Colesevelam Hcl | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | suppressed |
| Perphenazine | Perphenazine | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Verapamil Er | Verapamil Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 31 | suppressed |
| Valsartan | Valsartan | 31 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Methylprednisolone Acetate | Methylprednisolone Acetate | 30 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 28 | 21 |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Nitroglycerin | Nitroglycerin | 27 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 26 | suppressed |
| Naproxen | Naproxen | 25 | 16 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 24 | 11 |
| Icosapent Ethyl | Icosapent Ethyl | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Timolol Maleate | Timolol Maleate | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Anastrozole | Anastrozole | 22 | suppressed |
| Testosterone | Testosterone | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 20 | suppressed |
| Movantik | Naloxegol Oxalate | 20 | suppressed |
| Nabumetone | Nabumetone | 20 | suppressed |
| Nystop | Nystatin | 20 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 19 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 19 | suppressed |
| Glipizide Er | Glipizide | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Fluocinolone Acetonide Oil | Fluocinolone Acetonide Oil | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 17 | 17 |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 15 | suppressed |
| Austedo | Deutetrabenazine | 14 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 14 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 14 | 14 |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Dofetilide | Dofetilide | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Abilify Maintena | Aripiprazole | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $458.81 · 24 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, EVENITY, FREESTYLE LIBRE 3, INGREZZA, JARDIANCE, MOUNJARO, Ozempic, Rybelsus, UZEDY, VOQUEZNA, Wegovy, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error